The FDA approved a new monoclonal antibody to treat adults with moderate to severe plaque psoriasis.
The injectable brodalumab (Siliq, Valeant) is intended for patients who have failed to respond or stopped responding to other systemic therapy or phototherapy.
Psoriasis, an autoimmune disorder, occurs more commonly in patients with a family history of the disease, and most often begins in individuals between 15 and 35 years of age. The most common form of psoriasis is plaque psoriasis, in which